文献速递创伤骨科骨质疏松与代谢性骨病

二次骨折预防中骨活性药物使用的治疗目标与公平性:系统综述与荟萃分析

Examining treatment targets and equity in bone-active medication use within secondary fracture prevention: a systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2024-05-14

该系统综述纳入122项研究、114个项目,评估脆性骨折患者在二次骨折预防项目中接受骨活性药物处方与启动治疗的比例。汇总处方率为77%,估计治疗启动率为71%;骨折联络服务与其他项目的治疗启动率无显著差异。仅年龄、性别和社会经济地位在所有研究中作为公平性变量被报告。

要点

  • 汇总处方率为77%,估计治疗启动率为71%。
  • 骨折联络服务与其他项目的治疗启动率无显著差异。
  • 仅年龄、性别和社会经济地位在所有研究中作为公平性变量被报告。

核心结论

  • 该系统综述强调骨折后干预需要标准化报告指南。
  • 在健康结局分析中考虑公平性分层因素将有助于解决不平等并提高二次骨折预防项目的整体质量和覆盖范围。

研究设计与样本

  • 系统综述与单组比例荟萃分析,纳入122项研究、覆盖114个项目。
  • 评估脆性骨折患者中被指示接受药物治疗、收到骨活性药物处方及启动处方药物的比例,并分析年龄、性别、社会性别、种族、教育、收入、地理位置等公平性相关变量。

主要发现

  • 汇总处方率为77%,估计治疗启动率为71%。
  • 亚组分析显示骨折联络服务与其他项目之间的治疗启动率无显著差异。
  • 在所有研究中,年龄、性别和社会经济地位是仅有的与治疗结局相关的公平性变量报告。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This systematic review seeks to evaluate the proportion of fragility fracture patients screened in secondary fracture prevention programs who were indicated for pharmacological treatment, received prescriptions for bone-active medications, and initiated the prescribed medication. Additionally, the study aims to analyze equity in pharmacological treatment by examining equity-related variables including age, sex, gender, race, education, income, and geographic location. METHODS: We conducted a systematic review to ascertain the proportion of fragility fracture patients indicated for treatment who received prescriptions and/or initiated bone-active medication through secondary fracture prevention programs. We also examined treatment indications reported in studies and eligibility criteria to confirm patients who were eligible for treatment. To compute the pooled proportions for medication prescription and initiation, we carried out a single group proportional meta-analysis. We also extracted the proportions of patients who received a prescription and/or began treatment based on age, sex, race, education, socioeconomic status, location, and chronic conditions. RESULTS: This review included 122 studies covering 114 programs. The pooled prescription rate was 77%, and the estimated medication initiation rate was 71%. Subgroup analysis revealed no significant difference in treatment initiation between the Fracture Liaison Service and other programs. Across all studies, age, sex, and socioeconomic status were the only equity variables reported in relation to treatment outcomes. CONCLUSION: Our systematic review emphasizes the need for standardized reporting guidelines in post-fracture interventions. Moreover, considering equity stratifiers in the analysis of health outcomes will help address inequities and improve the overall quality and reach of secondary fracture prevention programs.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ali A, Huszti E, Noordin S, et al. Examining treatment targets and equity in bone-active medication use within secondary fracture prevention: a systematic review and meta-analysis. Osteoporos Int. 2024. PMID: 38740589. doi:10.1007/s00198-024-07078-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。